Immune Pharmaceuticals Inc (NASDAQ:IMNP) traded up 9.1% during trading on Thursday . The stock traded as high as $0.56 and last traded at $0.50. 1,089,767 shares traded hands during trading, a decline of 56% from the average session volume of 2,468,074 shares. The stock had previously closed at $0.55.
Several equities research analysts have commented on the stock. ValuEngine raised shares of Immune Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Maxim Group assumed coverage on shares of Immune Pharmaceuticals in a research report on Friday, January 5th. They set a “buy” rating and a $3.00 price target on the stock.
The company has a debt-to-equity ratio of 3.04, a quick ratio of 0.03 and a current ratio of 0.03.
An institutional investor recently raised its position in Immune Pharmaceuticals stock. Susquehanna International Group LLP increased its position in Immune Pharmaceuticals Inc (NASDAQ:IMNP) by 41.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 69,805 shares of the biopharmaceutical company’s stock after purchasing an additional 20,488 shares during the quarter. Susquehanna International Group LLP owned approximately 0.69% of Immune Pharmaceuticals worth $215,000 as of its most recent SEC filing. Institutional investors own 1.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Immune Pharmaceuticals (IMNP) Trading -9.1% Higher” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/02/10/immune-pharmaceuticals-imnp-trading-9-1-higher.html.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.